메뉴 건너뛰기




Volumn 8, Issue , 2013, Pages 87-100

Rituximab for the treatment of rheumatoid arthritis: An update

Author keywords

B cell depletion; Biologics; Prognosis; Rheumatoid arthritis

Indexed keywords

CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PLACEBO; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

EID: 84891619784     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S41645     Document Type: Review
Times cited : (137)

References (96)
  • 1
    • 84855172814 scopus 로고    scopus 로고
    • The pathogenesis of rheumatoid arthritis
    • McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-2219.
    • (2011) N Engl J Med , vol.365 , Issue.23 , pp. 2205-2219
    • McInnes, I.B.1    Schett, G.2
  • 3
    • 84863861008 scopus 로고    scopus 로고
    • Understanding the dynamics: Pathways involved in the pathogenesis of rheumatoid arthritis
    • Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5: v3-v11.
    • (2012) Rheumatology (Oxford) , vol.51 , Issue.SUPPL. 5
    • Choy, E.1
  • 4
    • 79953162113 scopus 로고    scopus 로고
    • Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis
    • Klareskog L, Malmström V, Lundberg K, Padyukov L, Alfredsson L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin Immunol. 2011;23(2):92-98.
    • (2011) Semin Immunol , vol.23 , Issue.2 , pp. 92-98
    • Klareskog, L.1    Malmström, V.2    Lundberg, K.3    Padyukov, L.4    Alfredsson, L.5
  • 5
    • 84869395513 scopus 로고    scopus 로고
    • B-cell therapies for rheumatoid arthritis
    • Scher JU. B-cell therapies for rheumatoid arthritis. Bull NYU Hosp Jt Dis. 2012;70(3):200-203.
    • (2012) Bull NYU Hosp Jt Dis , vol.70 , Issue.3 , pp. 200-203
    • Scher, J.U.1
  • 6
    • 24944472774 scopus 로고    scopus 로고
    • B cells: A fundamental role in the pathogenesis of rheumatoid arthritis?
    • Oxford
    • Panayi GS. B cells: a fundamental role in the pathogenesis of rheumatoid arthritis? Rheumatology (Oxford). 2005;44 Suppl 2:ii3-ii7.
    • (2005) Rheumatology , vol.44 , Issue.SUPPL. 2
    • Panayi, G.S.1
  • 7
  • 8
    • 0026031973 scopus 로고
    • Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells
    • Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med. 1991;173(2):487-489.
    • (1991) J Exp Med , vol.173 , Issue.2 , pp. 487-489
    • Roosnek, E.1    Lanzavecchia, A.2
  • 9
    • 77950205489 scopus 로고    scopus 로고
    • B cells in the pathogenesis and treatment of rheumatoid arthritis
    • Marston B, Palanichamy A, Anolik JH. B cells in the pathogenesis and treatment of rheumatoid arthritis. Curr Opin Rheumatol. 2010;22(3): 307-315.
    • (2010) Curr Opin Rheumatol , vol.22 , Issue.3 , pp. 307-315
    • Marston, B.1    Palanichamy, A.2    Anolik, J.H.3
  • 10
    • 0034283663 scopus 로고    scopus 로고
    • B lymphocyte-derived IL-16 attracts dendritic cells and Th cells
    • Kaser A, Dunzendorfer S, Offner FA, et al. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells. J Immunol. 2000;165(5): 2474-2480.
    • (2000) J Immunol , vol.165 , Issue.5 , pp. 2474-2480
    • Kaser, A.1    Dunzendorfer, S.2    Offner, F.A.3
  • 11
    • 0033033201 scopus 로고    scopus 로고
    • Do self-perpetuating B lymphocytes drive human autoimmune disease?
    • Edwards JC, Cambridge G, Abrahams VM. Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology. 1999;97(2):188-196.
    • (1999) Immunology , vol.97 , Issue.2 , pp. 188-196
    • Edwards, J.C.1    Cambridge, G.2    Abrahams, V.M.3
  • 12
    • 84862186837 scopus 로고    scopus 로고
    • Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases
    • Corsiero E, Bombardieri M, Manzo A, Bugatti S, Uguccioni M, Pitzalis C. Role of lymphoid chemokines in the development of functional ectopic lymphoid structures in rheumatic autoimmune diseases. Immunol Lett. 2012;145(1-2):62-67.
    • (2012) Immunol Lett , vol.145 , Issue.1-2 , pp. 62-67
    • Corsiero, E.1    Bombardieri, M.2    Manzo, A.3    Bugatti, S.4    Uguccioni, M.5    Pitzalis, C.6
  • 13
    • 79952011168 scopus 로고    scopus 로고
    • CXCL13: A novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis
    • Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL. CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology (Oxford). 2011;50(3):603-610.
    • (2011) Rheumatology (Oxford) , vol.50 , Issue.3 , pp. 603-610
    • Rosengren, S.1    Wei, N.2    Kalunian, K.C.3    Kavanaugh, A.4    Boyle, D.L.5
  • 15
    • 33745263037 scopus 로고    scopus 로고
    • Rituximab, an anti-cd20 monoclonal antibody: History and mechanism of action
    • Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6(5 Pt 1): 859-866.
    • (2006) Am J Transplant , vol.6 , Issue.5 PART 1 , pp. 859-866
    • Pescovitz, M.D.1
  • 17
    • 33845596250 scopus 로고    scopus 로고
    • Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy
    • Leandro MJ, Cooper N, Cambridge G, Ehrenstein MR, Edwards JC. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. Rheumatology (Oxford). 2007;46(1):29-36.
    • (2007) Rheumatology (Oxford) , vol.46 , Issue.1 , pp. 29-36
    • Leandro, M.J.1    Cooper, N.2    Cambridge, G.3    Ehrenstein, M.R.4    Edwards, J.C.5
  • 18
    • 33746942234 scopus 로고    scopus 로고
    • Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis
    • Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377-2386.
    • (2006) Arthritis Rheum , vol.54 , Issue.8 , pp. 2377-2386
    • Roll, P.1    Palanichamy, A.2    Kneitz, C.3    Dorner, T.4    Tony, H.P.5
  • 19
    • 79953679566 scopus 로고    scopus 로고
    • Reduced-dose rituximab in rheumatoid arthritis: Efficacy depends on degree of B cell depletion
    • Vital EM, Rawstron AC, Dass S, et al. Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion. Arthritis Rheum. 2011;63(3):603-608.
    • (2011) Arthritis Rheum , vol.63 , Issue.3 , pp. 603-608
    • Vital, E.M.1    Rawstron, A.C.2    Dass, S.3
  • 20
    • 38149044612 scopus 로고    scopus 로고
    • Synovial tissue response to rituximab: Mechanism of action and identification of biomarkers of response
    • Thurlings RM, Vos K, Wijbrandts CA, Zwinderman AH, Gerlag DM, Tak PP. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7): 917-925.
    • (2008) Ann Rheum Dis , vol.67 , Issue.7 , pp. 917-925
    • Thurlings, R.M.1    Vos, K.2    Wijbrandts, C.A.3    Zwinderman, A.H.4    Gerlag, D.M.5    Tak, P.P.6
  • 21
    • 77956391149 scopus 로고    scopus 로고
    • AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
    • Gottenberg JE, Ravaud P, Bardin T, et al; AutoImmunity and Rituximab registry and French Society of Rheumatology. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(9):2625-2632.
    • (2010) Arthritis Rheum , vol.62 , Issue.9 , pp. 2625-2632
    • Gottenberg, J.E.1    Ravaud, P.2    Bardin, T.3
  • 22
    • 0035093233 scopus 로고    scopus 로고
    • Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes
    • Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40(2):205-211.
    • (2001) Rheumatology (Oxford) , vol.40 , Issue.2 , pp. 205-211
    • Edwards, J.C.1    Cambridge, G.2
  • 23
    • 0036676817 scopus 로고    scopus 로고
    • Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells
    • De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum. 2002;46(8):2029-2033.
    • (2002) Arthritis Rheum , vol.46 , Issue.8 , pp. 2029-2033
    • de Vita, S.1    Zaja, F.2    Sacco, S.3    de Candia, A.4    Fanin, R.5    Ferraccioli, G.6
  • 24
    • 1842554935 scopus 로고    scopus 로고
    • Improvement of refractory rheumatoid arthritis after depletion of B cells
    • Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol. 2004;33(2): 82-86.
    • (2004) Scand J Rheumatol , vol.33 , Issue.2 , pp. 82-86
    • Kneitz, C.1    Wilhelm, M.2    Tony, H.P.3
  • 25
    • 2942537697 scopus 로고    scopus 로고
    • Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    • Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581.
    • (2004) N Engl J Med , vol.350 , Issue.25 , pp. 2572-2581
    • Edwards, J.C.1    Szczepanski, L.2    Szechinski, J.3
  • 26
    • 33646483031 scopus 로고    scopus 로고
    • The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial
    • Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al; DANCER Study Group. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 2006;54(5):1390-1400.
    • (2006) Arthritis Rheum , vol.54 , Issue.5 , pp. 1390-1400
    • Emery, P.1    Fleischmann, R.2    Filipowicz-Sosnowska, A.3
  • 27
    • 77955738274 scopus 로고    scopus 로고
    • Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR)
    • Rubbert-Roth A, Tak PP, Zerbini C, et al; MIRROR Trial Investigators. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford). 2010;49(9): 1683-1693.
    • (2010) Rheumatology (Oxford) , vol.49 , Issue.9 , pp. 1683-1693
    • Rubbert-Roth, A.1    Tak, P.P.2    Zerbini, C.3
  • 28
    • 77955896561 scopus 로고    scopus 로고
    • Efficacy and safety of different doses and retreatment of rituximab: A randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
    • Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis. 2010;69(9):1629-1635.
    • (2010) Ann Rheum Dis , vol.69 , Issue.9 , pp. 1629-1635
    • Emery, P.1    Deodhar, A.2    Rigby, W.F.3
  • 29
    • 33746961890 scopus 로고    scopus 로고
    • Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
    • Cohen SB, Emery P, Greenwald MW, et al.; REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
    • (2006) Arthritis Rheum , vol.54 , Issue.9 , pp. 2793-2806
    • Cohen, S.B.1    Emery, P.2    Greenwald, M.W.3
  • 30
    • 77951777466 scopus 로고    scopus 로고
    • Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: Results from the SUNRISE trial
    • Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol. 2010;37(5):917-927.
    • (2010) J Rheumatol , vol.37 , Issue.5 , pp. 917-927
    • Mease, P.J.1    Cohen, S.2    Gaylis, N.B.3
  • 31
    • 78650645377 scopus 로고    scopus 로고
    • Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: The IMAGE trial
    • IMAGE Investigators
    • Tak PP, Rigby WF, Rubbert-Roth A, et al; IMAGE Investigators. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. 2011;70(1):39-46.
    • (2011) Ann Rheum Dis , vol.70 , Issue.1 , pp. 39-46
    • Tak, P.P.1    Rigby, W.F.2    Rubbert-Roth, A.3
  • 32
    • 79953718761 scopus 로고    scopus 로고
    • Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: Results from a randomized controlled trial
    • Greenwald MW, Shergy WJ, Kaine JL, Sweetser MT, Gilder K, Linnik MD. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial. Arthritis Rheum. 2011;63(3):622-632.
    • (2011) Arthritis Rheum , vol.63 , Issue.3 , pp. 622-632
    • Greenwald, M.W.1    Shergy, W.J.2    Kaine, J.L.3    Sweetser, M.T.4    Gilder, K.5    Linnik, M.D.6
  • 33
    • 77953715791 scopus 로고    scopus 로고
    • Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate
    • Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. Ann Rheum Dis. 2010;69(6):1158-1161.
    • (2010) Ann Rheum Dis , vol.69 , Issue.6 , pp. 1158-1161
    • Cohen, S.B.1    Keystone, E.2    Genovese, M.C.3
  • 34
    • 82755176118 scopus 로고    scopus 로고
    • Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: The RESET Trial
    • Haraoui B, Bokarewa M, Kallmeyer I, Bykerk VP; RESET Investigators. Safety and effectiveness of rituximab in patients with rheumatoid arthritis following an inadequate response to 1 prior tumor necrosis factor inhibitor: the RESET Trial. J Rheumatol. 2011;38(12): 2548-2556.
    • (2011) J Rheumatol , vol.38 , Issue.12 , pp. 2548-2556
    • Haraoui, B.1    Bokarewa, M.2    Kallmeyer, I.3    Bykerk, V.P.4    Investigators, R.E.S.E.T.5
  • 35
    • 84867404092 scopus 로고    scopus 로고
    • Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: The MIRAR Study
    • MIRAR Study Group
    • Gomez-Reino JJ, Maneiro JR, Ruiz J, Roselló R, Sanmarti R, Romero AB; MIRAR Study Group. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis. 2012;71(11):1861-1864.
    • (2012) Ann Rheum Dis , vol.71 , Issue.11 , pp. 1861-1864
    • Gomez-Reino, J.J.1    Maneiro, J.R.2    Ruiz, J.3    Roselló, R.4    Sanmarti, R.5    Romero, A.B.6
  • 36
    • 84857233786 scopus 로고    scopus 로고
    • Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE
    • Tak PP, Rigby W, Rubbert-Roth A, et al. Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis. 2012;71(3):351-357.
    • (2012) Ann Rheum Dis , vol.71 , Issue.3 , pp. 351-357
    • Tak, P.P.1    Rigby, W.2    Rubbert-Roth, A.3
  • 37
    • 2342551979 scopus 로고    scopus 로고
    • Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
    • 20000223 Study Group
    • Genovese MC, Cohen S, Moreland L, et al; 20000223 Study Group. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 2004;50(5):1412-1419.
    • (2004) Arthritis Rheum , vol.50 , Issue.5 , pp. 1412-1419
    • Genovese, M.C.1    Cohen, S.2    Moreland, L.3
  • 38
    • 33749365296 scopus 로고    scopus 로고
    • Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study
    • Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum. 2006;54(9):2807-2816.
    • (2006) Arthritis Rheum , vol.54 , Issue.9 , pp. 2807-2816
    • Weinblatt, M.1    Combe, B.2    Covucci, A.3    Aranda, R.4    Becker, J.C.5    Keystone, E.6
  • 39
    • 77954583868 scopus 로고    scopus 로고
    • Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers
    • Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28(1 Suppl 57):81-83.
    • (2010) Clin Exp Rheumatol , vol.28 , Issue.1 SUPPL. 57 , pp. 81-83
    • Assmann, G.1    Pfreundschuh, M.2    Voswinkel, J.3
  • 40
    • 51649108185 scopus 로고    scopus 로고
    • Rituximab is useful in the treatment of Felty's syndrome
    • Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty's syndrome. Am J Ther. 2008;15(4):321-322.
    • (2008) Am J Ther , vol.15 , Issue.4 , pp. 321-322
    • Chandra, P.A.1    Margulis, Y.2    Schiff, C.3
  • 42
    • 84891591822 scopus 로고    scopus 로고
    • Low- versus high-dose rituximab for rheumatoid arthritis: A systematic review and meta-analysis
    • Bredemeier M, de Oliveira FK, Rocha CM. Low- versus high-dose rituximab for rheumatoid arthritis: A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2013.
    • (2013) Arthritis Care Res (Hoboken)
    • Bredemeier, M.1    de Oliveira, F.K.2    Rocha, C.M.3
  • 43
    • 84881119287 scopus 로고    scopus 로고
    • Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: Secondary analysis from a large clinical trial
    • Baker JF, Ostergaard M, Emery P, et al. Early MRI measures independently predict 1-year and 2-year radiographic progression in rheumatoid arthritis: secondary analysis from a large clinical trial. Ann Rheum Dis. 2013.
    • (2013) Ann Rheum Dis
    • Baker, J.F.1    Ostergaard, M.2    Emery, P.3
  • 44
    • 79955806071 scopus 로고    scopus 로고
    • Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
    • Rituximab Consensus Expert Committee
    • Buch MH, Smolen JS, Betteridge N, et al; Rituximab Consensus Expert Committee. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909-920.
    • (2011) Ann Rheum Dis , vol.70 , Issue.6 , pp. 909-920
    • Buch, M.H.1    Smolen, J.S.2    Betteridge, N.3
  • 45
    • 77951830908 scopus 로고    scopus 로고
    • Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: Retrospective arthritis cohort study
    • Bastian H, Zinke S, Egerer K, et al. Effects of early rituximab retreatment in rheumatoid arthritis patients with an inadequate response after the first cycle: retrospective arthritis cohort study. J Rheumatol. 2010;37(5):1069-1071.
    • (2010) J Rheumatol , vol.37 , Issue.5 , pp. 1069-1071
    • Bastian, H.1    Zinke, S.2    Egerer, K.3
  • 46
    • 84857238587 scopus 로고    scopus 로고
    • Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: Results of a 1-year follow-up study from the CERERRA collaboration
    • Chatzidionysiou K, Lie E, Nasonov E, et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis. 2012;71(3):374-377.
    • (2012) Ann Rheum Dis , vol.71 , Issue.3 , pp. 374-377
    • Chatzidionysiou, K.1    Lie, E.2    Nasonov, E.3
  • 47
    • 80051473134 scopus 로고    scopus 로고
    • Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: Pooled data from 10 European registries
    • Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70(9):1575-1580.
    • (2011) Ann Rheum Dis , vol.70 , Issue.9 , pp. 1575-1580
    • Chatzidionysiou, K.1    Lie, E.2    Nasonov, E.3
  • 48
    • 54949129325 scopus 로고    scopus 로고
    • Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
    • Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008;58(10):2993-2999.
    • (2008) Arthritis Rheum , vol.58 , Issue.10 , pp. 2993-2999
    • Dass, S.1    Rawstron, A.C.2    Vital, E.M.3    Henshaw, K.4    McGonagle, D.5    Emery, P.6
  • 49
    • 84857536861 scopus 로고    scopus 로고
    • Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs
    • Narvaez J, Díaz-Torné C, Ruiz JM, et al. Predictors of response to rituximab in patients with active rheumatoid arthritis and inadequate response to anti-TNF agents or traditional DMARDs. Clin Exp Rheumatol. 2011;29(6):991-997.
    • (2011) Clin Exp Rheumatol , vol.29 , Issue.6 , pp. 991-997
    • Narvaez, J.1    Díaz-Torné, C.2    Ruiz, J.M.3
  • 50
    • 84875719130 scopus 로고    scopus 로고
    • Predictive factors of rituximab response in rheumatoid arthritis: Results from a French university hospital
    • Couderc M, Mathieu S, Pereira B, Glace B, Soubrier M. Predictive factors of rituximab response in rheumatoid arthritis: results from a French university hospital. Arthritis Care Res (Hoboken). 2013;65(4):648-652.
    • (2013) Arthritis Care Res (Hoboken) , vol.65 , Issue.4 , pp. 648-652
    • Couderc, M.1    Mathieu, S.2    Pereira, B.3    Glace, B.4    Soubrier, M.5
  • 51
    • 79953711736 scopus 로고    scopus 로고
    • B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study
    • Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933-938.
    • (2011) Arthritis Rheum , vol.63 , Issue.4 , pp. 933-938
    • Sellam, J.1    Hendel-Chavez, H.2    Rouanet, S.3
  • 52
    • 82455163823 scopus 로고    scopus 로고
    • Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment
    • Lal P, Su Z, Holweg CT, et al. Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum. 2011;63(12): 3681-3691.
    • (2011) Arthritis Rheum , vol.63 , Issue.12 , pp. 3681-3691
    • Lal, P.1    Su, Z.2    Holweg, C.T.3
  • 53
    • 73349104126 scopus 로고    scopus 로고
    • Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: Depletion of memory B cells correlates with clinical response
    • Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131.
    • (2009) Arthritis Res Ther , vol.11 , Issue.4
    • Nakou, M.1    Katsikas, G.2    Sidiropoulos, P.3
  • 54
    • 32444447885 scopus 로고    scopus 로고
    • Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis
    • Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613-620.
    • (2006) Arthritis Rheum , vol.54 , Issue.2 , pp. 613-620
    • Leandro, M.J.1    Cambridge, G.2    Ehrenstein, M.R.3    Edwards, J.C.4
  • 55
    • 65949099716 scopus 로고    scopus 로고
    • Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis
    • Möller B, Aeberli D, Eggli S, et al. Class-switched B cells display response to therapeutic B-cell depletion in rheumatoid arthritis. Arthritis Res Ther. 2009;11(3):R62.
    • (2009) Arthritis Res Ther , vol.11 , Issue.3
    • Möller, B.1    Aeberli, D.2    Eggli, S.3
  • 56
    • 84860898796 scopus 로고    scopus 로고
    • Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab
    • Ruyssen-Witrand A, Rouanet S, Combe B, et al. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2012;71(6): 875-877.
    • (2012) Ann Rheum Dis , vol.71 , Issue.6 , pp. 875-877
    • Ruyssen-Witrand, A.1    Rouanet, S.2    Combe, B.3
  • 57
    • 84875577862 scopus 로고    scopus 로고
    • Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients
    • Ruyssen-Witrand A, Rouanet S, Combe B, et al. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford). 2013;52(4):636-641.
    • (2013) Rheumatology (Oxford) , vol.52 , Issue.4 , pp. 636-641
    • Ruyssen-Witrand, A.1    Rouanet, S.2    Combe, B.3
  • 58
    • 84857501180 scopus 로고    scopus 로고
    • The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis
    • Fabris M, Quartuccio L, Lombardi S, et al. The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun Rev. 2012;11(5): 315-320.
    • (2012) Autoimmun Rev , vol.11 , Issue.5 , pp. 315-320
    • Fabris, M.1    Quartuccio, L.2    Lombardi, S.3
  • 59
    • 82455210480 scopus 로고    scopus 로고
    • Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis
    • Sellam J, Rouanet S, Hendel-Chavez H, et al. Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2011;63(12):3692-3701.
    • (2011) Arthritis Rheum , vol.63 , Issue.12 , pp. 3692-3701
    • Sellam, J.1    Rouanet, S.2    Hendel-Chavez, H.3
  • 60
    • 84883245346 scopus 로고    scopus 로고
    • CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis
    • Sellam J, Rouanet S, Hendel-Chavez H, et al. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2013;65(9):2253-2261.
    • (2013) Arthritis Rheum , vol.65 , Issue.9 , pp. 2253-2261
    • Sellam, J.1    Rouanet, S.2    Hendel-Chavez, H.3
  • 61
    • 80053124729 scopus 로고    scopus 로고
    • A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis
    • Owczarczyk K, Lal P, Abbas AR, et al. A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med. 2011;3(101):101-192.
    • (2011) Sci Transl Med , vol.3 , Issue.101 , pp. 101-192
    • Owczarczyk, K.1    Lal, P.2    Abbas, A.R.3
  • 62
    • 77949673916 scopus 로고    scopus 로고
    • Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials
    • van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-567.
    • (2010) J Rheumatol , vol.37 , Issue.3 , pp. 558-567
    • van Vollenhoven, R.F.1    Emery, P.2    Bingham III, C.O.3
  • 63
    • 27544508559 scopus 로고    scopus 로고
    • Tolerability and safety of rituximab (MabThera)
    • Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456-473.
    • (2005) Cancer Treat Rev , vol.31 , Issue.6 , pp. 456-473
    • Kimby, E.1
  • 64
    • 58349113392 scopus 로고    scopus 로고
    • Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: Meta-analyses of randomised placebo-controlled trials
    • Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68(1):25-32.
    • (2009) Ann Rheum Dis , vol.68 , Issue.1 , pp. 25-32
    • Salliot, C.1    Dougados, M.2    Gossec, L.3
  • 65
    • 79959790816 scopus 로고    scopus 로고
    • The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents
    • Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011;70(8):1401-1406.
    • (2011) Ann Rheum Dis , vol.70 , Issue.8 , pp. 1401-1406
    • Curtis, J.R.1    Xie, F.2    Chen, L.3
  • 66
    • 84881475884 scopus 로고    scopus 로고
    • Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
    • van Vollenhoven RF, Emery P, Bingham CO, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis. 2013;72(9):1496-1502.
    • (2013) Ann Rheum Dis , vol.72 , Issue.9 , pp. 1496-1502
    • van Vollenhoven, R.F.1    Emery, P.2    Bingham, C.O.3
  • 67
    • 37149035531 scopus 로고    scopus 로고
    • Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open-label extension analysis
    • Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12): 3896-3908.
    • (2007) Arthritis Rheum , vol.56 , Issue.12 , pp. 3896-3908
    • Keystone, E.1    Fleischmann, R.2    Emery, P.3
  • 68
    • 84877359983 scopus 로고    scopus 로고
    • Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections
    • Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk. 2013;13(2):106-111.
    • (2013) Clin Lymphoma Myeloma Leuk , vol.13 , Issue.2 , pp. 106-111
    • Casulo, C.1    Maragulia, J.2    Zelenetz, A.D.3
  • 69
    • 84865697163 scopus 로고    scopus 로고
    • Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia
    • Otremba MD, Adam SI, Price CC, Hohuan D, Kveton JF. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia. Am J Otolaryngol. 2012;33(5):619-622.
    • (2012) Am J Otolaryngol , vol.33 , Issue.5 , pp. 619-622
    • Otremba, M.D.1    Adam, S.I.2    Price, C.C.3    Hohuan, D.4    Kveton, J.F.5
  • 71
    • 84879702684 scopus 로고    scopus 로고
    • Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab
    • Gigi E, Georgiou T, Mougiou D, Boura P, Raptopoulou-Gigi M. Hepatitis B reactivation in a patient with rheumatoid arthritis with antibodies to hepatitis B surface antigen treated with rituximab. Hippokratia. 2013;17(1):91-93.
    • (2013) Hippokratia , vol.17 , Issue.1 , pp. 91-93
    • Gigi, E.1    Georgiou, T.2    Mougiou, D.3    Boura, P.4    Raptopoulou-Gigi, M.5
  • 72
    • 84855690103 scopus 로고    scopus 로고
    • Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis
    • Ghrénassia E, Mékinian A, Rouaghe S, Ganne N, Fain O. Reactivation of resolved hepatitis B during rituximab therapy for rheumatoid arthritis. Joint Bone Spine. 2012;79(1):100-101.
    • (2012) Joint Bone Spine , vol.79 , Issue.1 , pp. 100-101
    • Ghrénassia, E.1    Mékinian, A.2    Rouaghe, S.3    Ganne, N.4    Fain, O.5
  • 73
    • 84875624029 scopus 로고    scopus 로고
    • The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection
    • Chen YM, Chen HH, Lai KL, Hung WT, Lan JL, Chen DY. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection. Rheumatology (Oxford). 2013;52(4):697-704.
    • (2013) Rheumatology (Oxford) , vol.52 , Issue.4 , pp. 697-704
    • Chen, Y.M.1    Chen, H.H.2    Lai, K.L.3    Hung, W.T.4    Lan, J.L.5    Chen, D.Y.6
  • 74
    • 84875889933 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy: Why gray and white matter
    • Gheuens S, Wüthrich C, Koralnik IJ. Progressive multifocal leukoencephalopathy: why gray and white matter. Annu Rev Pathol. 2013;8:189-215.
    • (2013) Annu Rev Pathol , vol.8 , pp. 189-215
    • Gheuens, S.1    Wüthrich, C.2    Koralnik, I.J.3
  • 75
    • 77649139783 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression
    • Gheuens S, Pierone G, Peeters P, Koralnik IJ. Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression. J Neurol Neurosurg Psychiatry. 2010;81(3):247-254.
    • (2010) J Neurol Neurosurg Psychiatry , vol.81 , Issue.3 , pp. 247-254
    • Gheuens, S.1    Pierone, G.2    Peeters, P.3    Koralnik, I.J.4
  • 76
    • 80052777262 scopus 로고    scopus 로고
    • Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis
    • Clifford DB, Ances B, Costello C, et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol. 2011;68(9):1156-1164.
    • (2011) Arch Neurol , vol.68 , Issue.9 , pp. 1156-1164
    • Clifford, D.B.1    Ances, B.2    Costello, C.3
  • 77
    • 70350539709 scopus 로고    scopus 로고
    • Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis
    • Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum. 2009;60(11):3225-3228.
    • (2009) Arthritis Rheum , vol.60 , Issue.11 , pp. 3225-3228
    • Fleischmann, R.M.1
  • 78
    • 84859741498 scopus 로고    scopus 로고
    • Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases
    • Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res (Hoboken). 2012;64(4): 612-615.
    • (2012) Arthritis Care Res (Hoboken) , vol.64 , Issue.4 , pp. 612-615
    • Bharat, A.1    Xie, F.2    Baddley, J.W.3
  • 79
    • 84867401844 scopus 로고    scopus 로고
    • Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: A national population-based study
    • ARTIS Study Group
    • Arkema EV, van Vollenhoven RF, Askling J; ARTIS Study Group. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71(11):1865-1867.
    • (2012) Ann Rheum Dis , vol.71 , Issue.11 , pp. 1865-1867
    • Arkema, E.V.1    van Vollenhoven, R.F.2    Askling, J.3
  • 80
    • 78851471759 scopus 로고    scopus 로고
    • Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy
    • Sugauchi F, Tanaka Y, Kusumoto S, et al. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy. J Med Virol. 2011;83(3):412-418.
    • (2011) J Med Virol , vol.83 , Issue.3 , pp. 412-418
    • Sugauchi, F.1    Tanaka, Y.2    Kusumoto, S.3
  • 81
    • 70350066135 scopus 로고    scopus 로고
    • Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier
    • Fukushima N, Mizuta T, Tanaka M, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20(12):2013-2017.
    • (2009) Ann Oncol , vol.20 , Issue.12 , pp. 2013-2017
    • Fukushima, N.1    Mizuta, T.2    Tanaka, M.3
  • 82
    • 84891598263 scopus 로고    scopus 로고
    • Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study
    • Taiwan Cooperative Oncology Group
    • Hsu C, Tsou HH, Lin SJ, et al.; Taiwan Cooperative Oncology Group. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: A prospective study. Hepatology. 2013.
    • (2013) Hepatology
    • Hsu, C.1    Tsou, H.H.2    Lin, S.J.3
  • 83
    • 53749095132 scopus 로고    scopus 로고
    • Does rituximab really induce hepatitis C virus reactivation?
    • Ennishi D, Yokoyama M, Terui Y, et al. Does rituximab really induce hepatitis C virus reactivation? J Clin Oncol. 2008;26(28):4695-4696; author reply 4696.
    • (2008) J Clin Oncol , vol.26 , Issue.28 , pp. 4695-4696
    • Ennishi, D.1    Yokoyama, M.2    Terui, Y.3
  • 84
    • 41849148616 scopus 로고    scopus 로고
    • Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C
    • Dizdar O, Tapan U, Aksoy S, Harputluoglu H, Kilickap S, Barista I. Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C. Eur J Haematol. 2008;80(5):381-385.
    • (2008) Eur J Haematol , vol.80 , Issue.5 , pp. 381-385
    • Dizdar, O.1    Tapan, U.2    Aksoy, S.3    Harputluoglu, H.4    Kilickap, S.5    Barista, I.6
  • 85
    • 84866134351 scopus 로고    scopus 로고
    • Rituximab-based treatment, HCV replication, and hepatic flares
    • Sagnelli E, Pisaturo M, Sagnelli C, Coppola N. Rituximab-based treatment, HCV replication, and hepatic flares. Clin Dev Immunol. 2012;2012:945-950.
    • (2012) Clin Dev Immunol , vol.2012 , pp. 945-950
    • Sagnelli, E.1    Pisaturo, M.2    Sagnelli, C.3    Coppola, N.4
  • 86
    • 46849083324 scopus 로고    scopus 로고
    • Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response
    • Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937-941.
    • (2008) Ann Rheum Dis , vol.67 , Issue.7 , pp. 937-941
    • Oren, S.1    Mandelboim, M.2    Braun-Moscovici, Y.3
  • 87
    • 74849103999 scopus 로고    scopus 로고
    • Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab
    • van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75-81.
    • (2010) Arthritis Rheum , vol.62 , Issue.1 , pp. 75-81
    • van Assen, S.1    Holvast, A.2    Benne, C.A.3
  • 88
    • 77953125533 scopus 로고    scopus 로고
    • Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
    • Rehnberg M, Brisslert M, Amu S, Zendjanchi K, Håwi G, Bokarewa MI. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111.
    • (2010) Arthritis Res Ther , vol.12 , Issue.3
    • Rehnberg, M.1    Brisslert, M.2    Amu, S.3    Zendjanchi, K.4    Håwi, G.5    Bokarewa, M.I.6
  • 89
    • 79952693877 scopus 로고    scopus 로고
    • The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab
    • Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643-1648.
    • (2011) Vaccine , vol.29 , Issue.8 , pp. 1643-1648
    • Arad, U.1    Tzadok, S.2    Amir, S.3
  • 90
    • 74849096560 scopus 로고    scopus 로고
    • Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial
    • Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64-74.
    • (2010) Arthritis Rheum , vol.62 , Issue.1 , pp. 64-74
    • Bingham III, C.O.1    Looney, R.J.2    Deodhar, A.3
  • 91
    • 85056032923 scopus 로고    scopus 로고
    • Rituximab for refractory rheumatoid arthritis: A 24-week open-label prospective study
    • Ho LY, Mok CC, To CH, Anselm M, Cheung MY, Yu KL. Rituximab for refractory rheumatoid arthritis: a 24-week open-label prospective study. Open Rheumatol J. 2007;1:1-4.
    • (2007) Open Rheumatol J , vol.1 , pp. 1-4
    • Ho, L.Y.1    Mok, C.C.2    To, C.H.3    Anselm, M.4    Cheung, M.Y.5    Yu, K.L.6
  • 92
    • 35948960659 scopus 로고    scopus 로고
    • Rituximab for refractory polymyositis: An open-label prospective study
    • Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34(9):1864-1868.
    • (2007) J Rheumatol , vol.34 , Issue.9 , pp. 1864-1868
    • Mok, C.C.1    Ho, L.Y.2    To, C.H.3
  • 93
    • 70149093654 scopus 로고    scopus 로고
    • Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis?
    • Li EK, Tam LS, Zhu TY, et al. Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford). 2009;48(8):892-898.
    • (2009) Rheumatology (Oxford) , vol.48 , Issue.8 , pp. 892-898
    • Li, E.K.1    Tam, L.S.2    Zhu, T.Y.3
  • 94
    • 84867644293 scopus 로고    scopus 로고
    • Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china
    • Wu B, Wilson A, Wang FF, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012;7(10):e47373.
    • (2012) PLoS One , vol.7 , Issue.10
    • Wu, B.1    Wilson, A.2    Wang, F.F.3
  • 95
    • 84891616923 scopus 로고    scopus 로고
    • Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: Data from the Hong Kong Biologics Registry
    • abstract
    • Mok CC, Kwan C, Chan KY, et al. Retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and predictive factors for drug withdrawal: data from the Hong Kong Biologics Registry. [abstract]. Arthritis Rheum. 2012;64 Suppl 10:388.
    • (2012) Arthritis Rheum , vol.64 , Issue.SUPPL. 10 , pp. 388
    • Mok, C.C.1    Kwan, C.2    Chan, K.Y.3
  • 96
    • 84921292134 scopus 로고    scopus 로고
    • Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: Data from the Hong Kong Biologics Registry
    • Mok CC, Chan KY, Lee KL, et al. Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry. Int J Rheum Dis. 2013 [in press].
    • (2013) Int J Rheum Dis
    • Mok, C.C.1    Chan, K.2    Lee, K.L.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.